Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: A randomised trial

Thorax

Volumn 64, Issue 7, 2009, Pages 581-586

  Alonso Fernandez A ^a,b   Garcia Rio F ^c   Arias, M A ^d   Hernanz, A ^c   De La Pena M ^a,b   Pierola J ^a,b   Barcelo A ^a,b   Lopez Collazo E ^b,c   Agusti A ^a,c,e  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e Program of Epidemiology and Clinical Research CIMERA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; CATECHOLAMINE; NITRATE; NITRITE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GENDER; HUMAN; MALE; MIDDLE AGED; OXIDATIVE STRESS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHAM PROCEDURE; SLEEP APNEA SYNDROME; THERAPY EFFECT; TREATMENT DURATION; URINE LEVEL;

EID: 67650245608     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.100537     Document Type: Article

References (33)

1. Arias MA, Garcia-Rio F, Alonso-Fernandez A, et al. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation 2005;112:375-83.
2. Laaban JP, Pascal-Sebaoun S, Bloch E, et al. Ventricular systolic dysfunction in patients with obstructive sleep apnea syndrome. Chest 2002;122:1133-8.
3. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.
4. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829-36.
5. Resta O, Foschino-Barbaro MP, Bonfitto P, et al. Prevalence and mechanisms of diurnal hypercapnia in a sample of morbidly obese subjects with obstructive sleep apnoea. Respir Med 2000;94:240-6.
6. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19-25.
7. Ip MS, Lam B, Chan LY, et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000;162:2166- 71.
8. Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax 2000;55:1046-51.
9. Teramoto S, Kume H, Matsuse T, et al. Oxygen administration improves the serum level of nitric oxide metabolites in patients with obstructive sleep apnea syndrome. Sleep Med 2003;4:403-7.
10. Barcelo A, Miralles C, Barbe F, et al. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000;16:644-7.
11. Carpagnano GE, Kharitonov SA, Resta O, et al. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003;124:1386-92.
12. Hernandez C, Abreu J, Abreu P, et al. Efectos del tratamiento con CPAP nasal en el estrés oxidativo en pacientes con síndrome de apnea del sueño. Arch Bronconeumol 2006;42:125-9.
13. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004;27:123-8.
14. Minoguchi K, Yokoe T, Tanaka A, et al. Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J 2006;28:378-85.
15. Ozturk L, Mansour B, Yuksel M, et al. Lipid peroxidation and osmotic fragility of red blood cells in sleep-apnea patients. Clin Chim Acta 2003;332:83-8.
16. Svatikova A, Wolk R, Lerman LO, et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005;26:2435-9.
17. Wali SO, Bahammam AS, Massaeli H, et al. Susceptibility of LDL to oxidative stress in obstructive sleep apnea. Sleep 1998;21:290-6.
18. Barcelo A, Barbe F, de la PM, et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006;27:756-60.
19. Carpagnano GE, Kharitonov SA, Resta O, et al. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003;124:1386-92.
20. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002;165:934-9.
21. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000;162:566-70.
22. Farre R, Hernandez L, Montserrat JM, et al. Sham continuous positive airway pressure for placebo-controlled studies in sleep apnoea. Lancet 1999;353:1154.
23. Masa JF, Jimenez A, Duran J, et al. Alternative methods of titrating continuous positive airway pressure: a large multicenter study. Am J Respir Crit Care Med 2004;170:1218-24.
24. Ballester E, Solans M, Vila X, et al. Evaluation of a portable respiratory recording device for detecting apnoeas and hypopnoeas in subjects from a general population. Eur Respir J 2000;16:123-7.
25. Garcia-Rio F, Pino JM, Alonso A, et al. White coat hypertension in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2004;125:817-22.
26. Quinones MA, Waggoner AD, Reduto LA, et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981;64:744-53.
27. Alonso-Fernandez A, Garcia-Rio F, Arias MA, et al. Obstructive sleep apnoea-hypoapnoea syndrome reversibly depresses cardiac response to exercise. Eur Heart J 2006;27:207-15.
28. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103:1955-60.
29. Gross M, Steffes M, Jacobs DR, et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem 2005;51:125-31.
30. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990;87:9383-7.
31. Viinikka L. Nitric oxide as a challenge for the clinical chemistry laboratory. Scand J Clin Lab Invest 1996;56:577-81.
32. Lavie L, Hefetz A, Luboshitzky R, et al. Plasma levels of nitric oxide and L-arginine in sleep apnea patients: effects of nCPAP treatment. J Mol Neurosci 2003;21:57-63.
33. McQuillan LP, Leung GK, Marsden PA, et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994;267:H1921-7.